BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 32798000)

  • 1. Clinical and imaging findings in cervical cancer and their impact on FIGO and TNM staging - An analysis from the EMBRACE study.
    Knoth J; Pötter R; Jürgenliemk-Schulz IM; Haie-Meder C; Fokdal L; Sturdza A; Hoskin P; Mahantshetty U; Segedin B; Bruheim K; Wiebe E; Rai B; Cooper R; van der Steen-Banasik E; van Limbergen E; Pieters BR; Sundset M; Tan LT; Nout RA; Tanderup K; Kirisits C; Nesvacil N; Lindegaard JC; Schmid MP
    Gynecol Oncol; 2020 Oct; 159(1):136-141. PubMed ID: 32798000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncologic outcomes in the era of modern radiation therapy using FIGO 2018 staging system for cervical cancer.
    Brodeur MN; Dejean R; Beauchemin MC; Samouëlian V; Cormier B; Bacha OM; Warkus T; Barkati M
    Gynecol Oncol; 2021 Aug; 162(2):277-283. PubMed ID: 34059350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FIGO Classification 2018: Validation Study in Patients With Locally Advanced Cervix Cancer Treated With Chemoradiation.
    Raut A; Chopra S; Mittal P; Patil G; Mahantshetty U; Gurram L; Swamidas J; Ghosh J; Gulia S; Popat P; Deodhar K; Maheshwari A; Gupta S
    Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1248-1256. PubMed ID: 32681859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic value of FIGO staging defined by combining MRI and [
    Raffa S; Lanfranchi F; Satragno C; Giannelli F; Marcenaro M; Coco A; Cena SE; Sofia L; Marini C; Mammoliti S; Levaggi A; Tagliafico AS; Sambuceti G; Barra S; Morbelli S; Belgioia L; Bauckneht M
    Curr Probl Cancer; 2023 Dec; 47(6):101007. PubMed ID: 37684197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A volumetric analysis of GTV
    Jastaniyah N; Yoshida K; Tanderup K; Lindegaard JC; Sturdza A; Kirisits C; Šegedin B; Mahantshetty U; Rai B; Jürgenliemk-Schulz IM; Haie-Meder C; Banerjee S; Pötter R;
    Radiother Oncol; 2016 Sep; 120(3):404-411. PubMed ID: 27452409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-FDG-PET/CT is of limited value in primary staging of early stage cervical cancer.
    Driscoll DO; Halpenny D; Johnston C; Sheehy N; Keogan M
    Abdom Imaging; 2015 Jan; 40(1):127-33. PubMed ID: 25015401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PARa-aOrtic LymphAdenectomy in locally advanced cervical cancer (PAROLA trial): a GINECO, ENGOT, and GCIG study.
    Martinez A; Lecuru F; Bizzarri N; Chargari C; Ducassou A; Fagotti A; Fanfani F; Scambia G; Cibula D; Díaz-Feijoo B; Gil Moreno A; Angeles MA; Muallem MZ; Kohler C; Luyckx M; Kridelka F; Rychlik A; Gerestein KG; Heinzelmann V; Ramirez PT; Frumovitz M; Ferron G; Betrian S; Filleron T; Fotopoulou C; Querleu D;
    Int J Gynecol Cancer; 2023 Feb; 33(2):293-298. PubMed ID: 36717163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-treatment surgical para-aortic lymph node assessment in locally advanced cervical cancer.
    Brockbank E; Kokka F; Bryant A; Pomel C; Reynolds K
    Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD008217. PubMed ID: 23543561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved stratification of stage-specific survival for cervical uterine cancer by integrating FDG-PET/CT and MRI for lymph node staging in 2018 FIGO classification.
    Holm J; Gerke O; Vilstrup MH; Spasojevic D; Sponholtz SE; Jochumsen KM; Thomassen A; Hildebrandt MG; Jensen PT
    Gynecol Oncol; 2022 Nov; 167(2):152-158. PubMed ID: 36182533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early clinical outcome of coverage probability based treatment planning for simultaneous integrated boost of nodes in locally advanced cervical cancer.
    Lindegaard JC; Assenholt M; Ramlov A; Fokdal LU; Alber M; Tanderup K
    Acta Oncol; 2017 Nov; 56(11):1479-1486. PubMed ID: 28849684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surgical versus clinical staging prior to primary chemoradiation in patients with cervical cancer FIGO stages IIB-IVA: oncologic results of a prospective randomized international multicenter (Uterus-11) intergroup study.
    Marnitz S; Tsunoda AT; Martus P; Vieira M; Affonso Junior RJ; Nunes J; Budach V; Hertel H; Mustea A; Sehouli J; Scharf JP; Ulrich U; Ebert A; Piwonski I; Kohler C
    Int J Gynecol Cancer; 2020 Dec; 30(12):1855-1861. PubMed ID: 33293284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perioperative morbidity and rate of upstaging after laparoscopic staging for patients with locally advanced cervical cancer: results of a prospective randomized trial.
    Köhler C; Mustea A; Marnitz S; Schneider A; Chiantera V; Ulrich U; Scharf JP; Martus P; Vieira MA; Tsunoda A
    Am J Obstet Gynecol; 2015 Oct; 213(4):503.e1-7. PubMed ID: 25986030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of patients after extraperitoneal lymph node dissection for cervical cancer.
    Denschlag D; Gabriel B; Mueller-Lantzsch C; Tempfer C; Henne K; Gitsch G; Hasenburg A
    Gynecol Oncol; 2005 Mar; 96(3):658-64. PubMed ID: 15721408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the Role of F-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Scanning in the Staging of Patients With Stage IIIB Cervical Carcinoma and the Impact on Treatment Decisions.
    Morkel M; Ellmann A; Warwick J; Simonds H
    Int J Gynecol Cancer; 2018 Feb; 28(2):379-384. PubMed ID: 29324535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accuracy of preoperative cross-sectional imaging in cervical cancer patients undergoing primary radical surgery.
    Staley SA; Tucker KR; Gehrig PA; Clark LH
    Gynecol Oncol; 2021 Feb; 160(2):384-388. PubMed ID: 33213900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin Chemoradiotherapy vs Radiotherapy in FIGO Stage IIIB Squamous Cell Carcinoma of the Uterine Cervix: A Randomized Clinical Trial.
    Shrivastava S; Mahantshetty U; Engineer R; Chopra S; Hawaldar R; Hande V; Kerkar RA; Maheshwari A; Shylasree TS; Ghosh J; Bajpai J; Gurram L; Gulia S; Gupta S;
    JAMA Oncol; 2018 Apr; 4(4):506-513. PubMed ID: 29423520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. False negative rate at
    Gouy S; Seebacher V; Chargari C; Terroir M; Grimaldi S; Ilenko A; Maulard A; Genestie C; Leary A; Pautier P; Morice P; Deandreis D
    BMC Cancer; 2021 Feb; 21(1):135. PubMed ID: 33549033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Parametrial Response by Growth Pattern in Patients With International Federation of Gynecology and Obstetrics Stage IIB and IIIB Cervical Cancer: Analysis of Patients From a Prospective, Multicenter Trial (EMBRACE).
    Yoshida K; Jastaniyah N; Sturdza A; Lindegaard J; Segedin B; Mahantshetty U; Rai B; Jürgenliemk-Schulz I; Haie-Meder C; Sasaki R; Pötter R
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):788-96. PubMed ID: 26530747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic values of ADC
    Akkus Yildirim B; Onal C; Erbay G; Cem Guler O; Karadeli E; Reyhan M; Koc Z
    J Obstet Gynaecol; 2019 Feb; 39(2):224-230. PubMed ID: 30354907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of ultrasound in primary workup of cervical cancer staging (ESGO, ESTRO, ESP cervical cancer guidelines).
    Fischerová D; Cibula D
    Ceska Gynekol; 2019; 84(1):40-48. PubMed ID: 31213057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.